Neuropace
NPCE
113 hedge funds and large institutions have $422M invested in Neuropace in 2026 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 36 reducing their positions, and 18 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 36
21% more capital invested
Capital invested by funds: $348M → $422M (+$74.5M)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding
Funds holding: 113 → 113 (0)
0.63% less ownership
Funds ownership: 78.59% → 77.95% (-0.63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$6.46M |
| 2 |
BlackRock
New York
|
+$2.11M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.89M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.66M |
| 5 |
HWM
HighMark Wealth Management
St. Paul,
Minnesota
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$9.52M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2M |
| 3 |
TCM
Topline Capital Management
Santa Monica,
California
|
-$1.06M |
| 4 |
Renaissance Technologies
New York
|
-$1.01M |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$954K |
NPCE Hedge Fund Activity: Q2 2026 in Review
113 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q2 2026, worth a combined $422M — up 21% from $348M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NPCE positions and 18 closed out — a net gain of 1 holder — while 48 added to existing stakes and 36 trimmed.
The largest buyer was First Light Asset Management, adding an estimated $6.46M. The largest seller was OrbiMed, cutting an estimated $9.52M.
- 113 institutional investors held Neuropace (NPCE) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $422M of Neuropace stock for Q2 2026, up 21% quarter-over-quarter.
- 19 funds opened new Neuropace positions in Q2 2026 and 18 closed out, a net change of +1 holder.
- The largest Neuropace buyer in Q2 2026 was First Light Asset Management, an estimated $6.46M added.
- The largest Neuropace seller in Q2 2026 was OrbiMed, an estimated $9.52M sold.
Based on aggregated 13F filings for Q2 2026.